AVTE News and Press, Aerovate Therapeutics Inc. From 05/16/23

2023-05-16 04:18:57 ET Aerovate Therapeutics press release ( NASDAQ: AVTE ): Q1 GAAP EPS of -$0.67 misses by $0.07 . Cash, cash equivalents and short-term investments totaled $118.9 million as of March 31, 2023, compared to $129.2 million as of December 31, 2022. W...

Topline Phase 2b data now expected in the second quarter of 2024 for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) More than 100 sites activated in 20 countries with the pace of enrollment increasing Sufficiently funded into second ...

Summary Gossamer Bio, Inc.'s lead candidate - Seralutinib, indicated for Pulmonary Arterial Hypertension - met its primary endpoint in the Phase 2 TORREY study. Nevertheless, investors dumped the stock - due to Seralutinib's perceived inferiority to Merck's Sotatercept. On a 6-minut...

WALTHAM, Mass., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced the publication of Phase 1 ...

Aerovate Therapeutics press release ( NASDAQ: AVTE ): Q2 GAAP EPS of -$0.56 misses by $0.06 . Cash, cash equivalents and short-term investments totaled $142.6 million as of September 30, 2022, compared to $167.4 million as of December 31, 2021. We expect cash, cash...

WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, today announced financial results for t...

WALTHAM, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE) today presents the design of IMPAHCT (Inhaled iMatinib for Pulmonary Arterial Hypertension Clinical Trial; AV-101-002), a Phase 2b/Phase 3 trial investigating the safety and efficacy of AV-101 in ad...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Short-squeeze stocks continue to be a big deal for speculative traders and we’re helping them out with a list to keep in mind this week! That list comes from Fintel and its Short Sque...

Summary Baker Brothers’ 13F portfolio value increased from $17.40B to $17.63B this quarter. Global Blood Therapeutics, Horizon Therapeutics, and Kymera Therapeutics were increased during the quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, a...

Aerovate Therapeutics press release ( NASDAQ: AVTE ): Q2 GAAP EPS of -$0.49 misses by $0.03 . Cash, cash equivalents and short-term investments totaled $152.0 million as of June 30, 2022, compared to $167.4 million as of December 31, 2021. For further details see...